SCHEMBL1473366

SCHEMBL1473366

COc1cc(NC(=O)C(=O)Nc2ccccc2)ccc1-c1cnco1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
IMPDH2 P12268 17/20 1.00
IMPDH1 P20839 4/20 0.76
AAK1 Q2M2I8 4/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7549462 0.92 IMPDH2 (0.85) IMPDH2IMPDH1AAK1
SCHEMBL7543846 0.92 IMPDH2 (0.88) IMPDH2IMPDH1AAK1
SCHEMBL1475741 0.91 IMPDH2 (1.00) IMPDH2IMPDH1AAK1
SCHEMBL1472764 0.91 IMPDH2 (0.83) IMPDH2IMPDH1AAK1
SCHEMBL3939748 0.91 IMPDH2 (0.83) IMPDH2IMPDH1AAK1
SCHEMBL14518602 0.91 IMPDH2 (0.83) IMPDH2IMPDH1AAK1
SCHEMBL6488186 0.90 IMPDH2 (0.81) IMPDH2IMPDH1AAK1
SCHEMBL3995894 0.90 IMPDH2 (0.82) IMPDH2IMPDH1AAK1
SCHEMBL1475387 0.90 IMPDH2 (0.82) IMPDH2IMPDH1AAK1
SCHEMBL1474596 0.90 IMPDH2 (0.88) IMPDH2IMPDH1AAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1127054-A4 NOVEL INHIBITORS OF IMPDH ENZYME BRISTOL MYERS SQUIBB CO (US) 2006-11-02 EP claimed
US-20040102497-A1 Novel inhibitors of IMPDH enzyme GU HENRY H (US) 2004-05-27 US claimed
US-20040082562-A1 Novel inhibitors of IMPDH enzyme GU HENRY H (US) 2004-04-29 US claimed
US-6624184-B1 Identification of the inhibitors of IMPDH (inosine-5'-monophosphate dehydrogenase). The compounds and pharmaceutical compositions disclosed herein are useful in treating or preventing IMPDH associated disorders, and BRISTOL-MYERS SQUIBB COMPANY 2003-09-23 US claimed
EP-1127054-A1 NOVEL INHIBITORS OF IMPDH ENZYME BRISTOL-MYERS SQUIBB COMPANY (US) 2001-08-29 EP claimed
WO-2000026197-A9 NOVEL INHIBITORS OF IMPDH ENZYME BRISTOL MYERS SQUIBB CO (US) 2000-10-26 WO claimed
WO-2000026197-A1 NOVEL INHIBITORS OF IMPDH ENZYME BRISTOL-MYERS SQUIBB COMPANY (US) 2000-05-11 WO claimed
EP-2803357-B1 Angiogenesis inhibitors UNIV JOHNS HOPKINS (US) 2020-11-18 EP disclosed
US-9642865-B2 Angiogenesis inhibitors THE JOHNS HOPKINS UNIVERSITY (US) 2017-05-09 US disclosed
US-8980930-B2 Angiogenesis inhibitors THE JOHNS HOPKINS UNIVERSITY (US) 2015-03-17 US disclosed
US-20150056267-A1 ANGIOGENESIS INHIBITORS UNIV JOHNS HOPKINS (US) 2015-02-26 US disclosed
EP-2803357-A2 Angiogenesis inhibitors THE JOHNS-HOPKINS UNIVERSITY (US) 2014-11-19 EP disclosed
US-20130101657-A1 ANGIOGENESIS INHIBITORS THE JOHNS HOPKINS UNIVERSITY (US) 2013-04-25 US disclosed
WO-2006004795-A2 ANGIOGENESIS INHIBITORS THE JOHNS HOPKINS UNIVERSITY (US) 2006-01-12 WO disclosed
US-20040102497-A1 Novel inhibitors of IMPDH enzyme GU HENRY H (US) 2004-05-27 US disclosed
US-20040082562-A1 Novel inhibitors of IMPDH enzyme GU HENRY H (US) 2004-04-29 US disclosed
US-6624184-B1 Identification of the inhibitors of IMPDH (inosine-5'-monophosphate dehydrogenase). The compounds and pharmaceutical compositions disclosed herein are useful in treating or preventing IMPDH associated disorders, and BRISTOL-MYERS SQUIBB COMPANY 2003-09-23 US disclosed
EP-1127054-A1 NOVEL INHIBITORS OF IMPDH ENZYME BRISTOL-MYERS SQUIBB COMPANY (US) 2001-08-29 EP disclosed
WO-2000026197-A9 NOVEL INHIBITORS OF IMPDH ENZYME BRISTOL MYERS SQUIBB CO (US) 2000-10-26 WO disclosed
WO-2000026197-A1 NOVEL INHIBITORS OF IMPDH ENZYME BRISTOL-MYERS SQUIBB COMPANY (US) 2000-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150056267-A1 ANGIOGENESIS INHIBITORS FLT1, VEGFA, FLT4 IMPDH2 2862/4885IMPDH1 2706/4885AAK1 793/4885
US-20040082562-A1 Novel inhibitors of IMPDH enzyme IMPDH1, IMPDH2, IMPA1 IMPDH2 2/4885IMPDH1 1/4885AAK1 2009/4885
US-20130101657-A1 ANGIOGENESIS INHIBITORS FLT1, VEGFA, FLT4 IMPDH2 2862/4885IMPDH1 2706/4885AAK1 793/4885
US-20040102497-A1 Novel inhibitors of IMPDH enzyme IMPDH1, IMPDH2, IMPA1 IMPDH2 2/4885IMPDH1 1/4885AAK1 2009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.